Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.
Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
June 6, 2023
Assignee:
HiberCell, Inc.
Inventors:
Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
January 14, 2022
Date of Patent:
June 6, 2023
Assignee:
Theravance Biopharma R&D IP, LLC
Inventors:
Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
Type:
Grant
Filed:
May 6, 2021
Date of Patent:
May 16, 2023
Assignee:
Cornell University
Inventors:
Joseph P. Vacca, Dansu Li, Sarah Bettigole
Abstract: The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans.
Abstract: Provided are an FGFR4 inhibitor with the structure of formula (I) and a preparation method and use thereof. The series of compounds of formula (I) have a very strong inhibitory effect on the FGFR4 kinase activity, and have a very high selectivity; and the same can be widely used to prepare drugs for treating cancers, in particular, liver cancer, stomach cancer, prostate cancer, skin cancer, ovarian cancer, lung cancer, breast cancer or colon cancer, and it is expected that the same can be developed into a new generation of FGFR4 inhibitor drugs.
Abstract: The present invention concerns a compound having the following formula (I): as well as its use as a medicament, especially for its use for treating viral infections.
Type:
Grant
Filed:
April 23, 2019
Date of Patent:
March 14, 2023
Assignees:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'ORLEANS, NEOVIRTECH
Inventors:
Luigi Agrofoglio, Vincent Roy, Coralie De Schutter, Maxime Bessieres, Franck Gallardo
Abstract: The embodiments of the present invention provide a series of thiamine compounds having a hydrocarbon group or a substituted hydrocarbon group attached at (I), wherein the compounds have an inhibitory effect on A?40 and/or A?42.
Abstract: Compounds are provided having Formula (I): wherein R, R1, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.
Type:
Grant
Filed:
September 25, 2018
Date of Patent:
February 21, 2023
Assignee:
IDEAYA BIOSCIENCES, INC.
Inventors:
Hilary Plake Beck, Leah Brigit Cleary, Michael Patrick Dillon, Marcos Gonzalez-Lopez, Luis Ruben P. Martinez, James Clifford Sutton, Jr.
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
Type:
Grant
Filed:
February 28, 2019
Date of Patent:
February 14, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Kap-Sun Yeung, Denis R. St. Laurent, David R. Langley, Paul Michael Scola
Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
Type:
Grant
Filed:
January 29, 2021
Date of Patent:
February 14, 2023
Assignees:
Mitobridge, Inc., The Salk Institute for Biological Studies
Inventors:
Michael Downes, Ronald M. Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type:
Grant
Filed:
July 16, 2020
Date of Patent:
February 7, 2023
Assignee:
Enanta Pharmaceuticals, Inc.
Inventors:
Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
Type:
Grant
Filed:
October 29, 2021
Date of Patent:
January 31, 2023
Assignee:
VENATORX PHARMACEUTICALS, INC.
Inventors:
Christopher J. Burns, Glen Coburn, Bin Liu, Jiangchao Yao, Christopher Benetatos, Steven A. Boyd, Stephen M. Condon, Thomas Haimowitz
Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
Type:
Grant
Filed:
April 6, 2020
Date of Patent:
January 31, 2023
Assignee:
Arixa Pharmaceuticals, Inc.
Inventors:
Eric M. Gordon, Matthew A. J. Duncton, John Freund
Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.
Type:
Grant
Filed:
April 16, 2018
Date of Patent:
January 17, 2023
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Andrew Baxter, Sophie Marie Bertrand, Matthew Campbell, Kenneth David Down, Curt Dale Haffner, Julie Nicole Hamblin, Zoe Alicia Henley, William Henry Miller, Eric Philippe Andre Talbot, Jonathan Andrew Taylor
Abstract: The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.
Type:
Grant
Filed:
November 8, 2019
Date of Patent:
January 17, 2023
Assignee:
Nimbus Artemis, Inc.
Inventors:
Silvana Marcel Leit de Moradei, Eric Therrien
Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
Type:
Grant
Filed:
April 27, 2021
Date of Patent:
January 10, 2023
Assignee:
Constellation Pharmaceuticals, Inc.
Inventors:
Francois Brucelle, Victor S. Gehling, Avinash Khanna